CARD19

Across TCGA pan-cancer cohorts, CARD19 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CARD19 data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CARD19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CARD19 expression acts as an unfavorable survival marker, although some lineages such as COAD and OV show a favorable association.

COAD, PDAC, and OV are the cancer types where CARD19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.912	.013	54	view →
PDAC	DFS	Quartile	III,IV	0.375	0.951	.004	13	view →
OV	DFS	Median	All	0.942	0.547	.003	8	view →
GBM	OS	Quartile	All	0.431	0.672	.024	6	view →
CCRCC	DFS	Tertile	All	1.000	0.686	.030	5	view →
LSCC	OS	Median	II,III,IV	0.775	1.000	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CARD19–COAD (DFS)

Open the COAD breakdown →